As 2023 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in atopic dermatitis this year.
The study reviewed the associations between more than 14,000 pediatric patients living in the Denver area and their proximity to major roadways. Patients presenting and meeting diagnostic criteria and codes for AD (n=7384) were measured and compared to a control group of pediatric patients without AD (n=7241).
Eczema prevalence increased overall over a 21-year period among children living with the chronic skin condition in the United States, with significant differences seen when potential contributions from race and ethnicity were considered.
In Latin America, the prevalence of atopic dermatitis (AD) is reportedly as much as 25% in children and 1%-3% in adults, according to numerous papers and studies on the disease. Historically, AD goes into remission in adolescence and adult life, with approximately 10%-30% of patients continuing to experience symptoms of AD in adulthood.
A study presented by Eric Lawrence Simpson, MD, FAAD showed that dupilumab (Dupixent) significantly improved signs and symptoms in patients with hand and foot atopic dermatitis and had an acceptable safety profile. The study results were unveiled during a late-breaking research session at the 2023 American Academy of Dermatology Meeting in New Orleans, Louisiana.
“I think sometimes you have the impression that dermatologists and allergists don't see eye-to-eye when it comes to food allergies in our atopic dermatitis patients, but I think many of us do and we have a lot to teach each,” said Lacey Kruse, MD, FAAD, pediatric dermatologist at Ann & Robert H Lurie Children’s Hospital of Chicago. She teamed up with Rachel Robison, MD, pediatric allergist at Monroe Carell Jr. Children’s Hospital at Vanderbilt, to translate guidelines into clinical practice.
Recent studies have shown that California wildfires, and the air pollution resulting from them, led a significant number of Californians to seek dermatologic treatment. Inflammatory skin conditions such as psoriasis and atopic dermatitis were among the most common.
Lanolin, known mainly for its emollient properties, has been named by the American Contact Dermatitis Society as the Contact Allergen of the Year for 2023. Lanolin is a complex mixture of high molecular weight esters, aliphatic alcohols, sterols, fatty acids, and hydrocarbons that has been widely used for centuries for its emollient properties. The prevalence of lanolin contact allergy in dermatitis patients varies from 1.2% to 6.9%.
Boxed warnings for JAK inhibitors, specifically for treating atopic dermatitis, tend to get in the way of providing the appropriate care to patients, according to Brett King, MD, PhD. At the 2023 Revolutionizing Atopic Dermatitis conference in Washington, DC, King discussed how boxed warnings for JAK inhibitors came to be, and reviewed data demonstrating that JAK inhibitors for atopic dermatitis are significantly safer than JAK inhibitors used to treat rheumatoid arthritis.
While engaging in physical activity can improve mental health symptoms, researchers said it can also exacerbate certain skin conditions, such as atopic dermatitis and chronic spontaneous urticaria.
Researchers assessed existing literature related to the topic of swimming and atopic dermatitis in order to pool data supporting the benefits and drawbacks of the activity. Additionally, they sought to analyze several factors, including components of water, exercise, skin barrier protection, and swimming gear.
For many patients suffering from eczema or sensitive skin, it can be difficult to find the right products to treat the skin without causing irritation. Renata Block, MMS, PA-C, a board-certified dermatology physician assistant at Advanced Dermatology and Aesthetic Medicine, LLC, in Chicago, Illinois, recently spoke to the founder of the Eczema Sample Store, a subscription service that brings smaller samples to patients trying to find the right products for their skin.
With advanced developments in atopic dermatitis (AD) treatments for pediatric patients and shared struggles to ensure patient adherence, course directors for the Society for Pediatric Dermatology 48th Annual Meeting in Asheville, North Carolina welcomed a panel of experts to delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.
Colleen Cotton, MD, is a board-certified dermatologist and pediatrician at Children's National Hospital and assistant professor of dermatology and pediatrics at George Washington School of Medicine in Washington, DC. She shared pearls about pediatric atopic dermatitis, how it's important to time biologic injections with live vaccinations, and how to have conversations about different treatment options with families.
As more topical treatments have entered the dermatology space over the years, topical steroid withdrawal (TSW), also known as red skin syndrome or topical steroid addiction, has led to widespread discussions about the potential implications of the prolonged use of topical corticosteroids.
Despite the tremendous impact of TSW, little is known about the effects of TSW, including how frequently it arises in patients, and there is limited research exploring this multifaceted and extreme corticosteroid reaction.
Understanding the clinical presentations in adult versus pediatric patients is crucial for making an accurate diagnosis and then developing an appropriate treatment regimen. In an interview with Dermatology Times, Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls.
The American Academy of Dermatology recently published new recommended guidelines for the management of atopic dermatitis (AD) using phototherapy and systemic therapies to include more recently approved biologics and Janus kinase inhibitors. After their comprehensive review, the guideline authors strongly recommend the use of dupilumab (Dupixent), tralokinumab (Adbry), baricitinib (Olumiant), abrocitinib (Cibinqo), and upadacitinib (Rinvoq); conditionally recommend phototherapy, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil; and do not recommend systemic corticosteroids.